Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced/Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06388031
What this trial is testing

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Who this might be right for
Non-small Cell Lung Cancer
Peking Union Medical College Hospital 27
Large-scale testing (Phase 3)Active Not RecruitingNCT05009836
What this trial is testing

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hutchmed 412
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Active Not RecruitingNCT04579380
What this trial is testing

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Who this might be right for
Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer 217
Large-scale testing (Phase 3)Looking for participantsNCT07170995
What this trial is testing

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 460
Not applicableStudy completedNCT03761901
What this trial is testing

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 141
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395677
What this trial is testing

AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 173
Testing effectiveness (Phase 2)Study completedNCT00047840
What this trial is testing

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Genzyme, a Sanofi Company 129
Testing effectiveness (Phase 2)Active Not RecruitingNCT05949606
What this trial is testing

SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 95
Early research (Phase 1)Study completedNCT01199068
What this trial is testing

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Daiichi Sankyo Co., Ltd. 15
Large-scale testing (Phase 3)Not Yet RecruitingNCT07821684
What this trial is testing

Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
AbbVie 660
Large-scale testing (Phase 3)Study completedNCT00364351
What this trial is testing

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Who this might be right for
Non Small Cell Lung Cancer
Genzyme, a Sanofi Company 1,574
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)Study completedNCT02039674
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Who this might be right for
Non-small Cell Lung Carcinoma
Merck Sharp & Dohme LLC 267
Large-scale testing (Phase 3)Not Yet RecruitingNCT07383116
What this trial is testing

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Who this might be right for
Non Squamous Non-small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd. 500
Testing effectiveness (Phase 2)Looking for participantsNCT06107686
What this trial is testing

YL202 in Selected Patients With Advanced Solid Tumors

Who this might be right for
NSCLCBreast CancerHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd. 200
Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Early research (Phase 1)Study completedNCT03565445
What this trial is testing

ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Astellas Pharma Global Development, Inc. 190
Large-scale testing (Phase 3)Study completedNCT02008227
What this trial is testing

Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 1,225
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Next Page